Publications by authors named "Jeremy Hoang"
Article Synopsis
- The study explores the use of an online clinical support tool designed to minimize judgment variability, or "noise," in prescribing radioactive iodine (RAI) for patients with differentiated thyroid cancer (DTC).
- It involved applying the tool to 103 patients treated from 2021-2022 and comparing it to 393 patients treated from 2017-2021, showing significant reductions in RAI dosages for intermediate and high-risk patients.
- The results indicate that the tool effectively reduces variability in treatment decisions without increasing recurrence rates, suggesting it's a beneficial resource for clinical practice in DTC management.
Article Synopsis
- Somatostatin receptor imaging using Ga-DOTATATE PET/CT enhances the diagnostic capabilities for medullary thyroid cancer (MTC), allowing for better understanding of tumor characteristics.
- In a study of 103 MTC patients, only 41% showed positive SST expression, but SST positivity did not correlate with survival benefits or imaging results.
- The findings suggest that the Total Lesion Activity (TLA) from Ga-DOTATATE PET/CT could help predict patient survival, while combining it with F-FDG-PET/CT may provide a more accurate assessment of metastatic disease.
Objective: We propose a new scoring system (I-PET) combining whole body scan (WBS) and FDG findings to identify patients who have or are likely to become refractory to radioactive iodine.
Design: Retrospective analysis of 142 patients age >18 with differentiated thyroid cancer who had a F-18 labelled fluoro-2-deoxyglucose ( F-FDG) positron emission tomography (PET) and WBS within a 6-month period between 2010 and 2020. Pairs of F-FDG PET and WBS were reviewed by three independent nuclear medicine physicians and an I-PET score was assigned: I-PET [0]: Iodine -ve/FDG -ve, I-PET [1]: Iodine +ve/FDG -ve, I-PET [2]: Iodine +ve/FDG +ve and I-PET [3]: Iodine -ve/FDG +ve.
The goal of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) is to treat metastasis and reduce recurrence risk. International guidelines provide broad risk stratification to aid treatment decisions, but a more nuanced approach to individualize care is warranted. We developed a predictive risk model for DTC.
View Article and Find Full Text PDFObjective: Our study aimed to analyse temporal trends in radioactive iodine (RAI) treatment for thyroid cancer over the past decade; to analyse key factors associated with clinical decisions in RAI dosing; and to confirm lower activities of RAI for low-risk patients were not associated with an increased risk of recurrence.
Methods: Retrospective analysis of 1,323 patients who received RAI at a quaternary centre in Australia between 2008 and 2018 was performed. Prospectively collected data included age, gender, histology, and American Joint Committee on Cancer stage (7th ed).
Objectives: Appendiceal neuroendocrine neoplasms (appNEN) generally carry a low recurrence risk. Ga-DOTATATE positron emission tomography (DOTA PET) is increasingly used as it is more sensitive than cross-sectional imaging. We hypothesize that early DOTA PET is unlikely to detect recurrent disease in patients with low-risk resected appNEN because of the delayed pattern of recurrence.
View Article and Find Full Text PDFContext: Diagnosis of paragangliomas (PGL) and phaeochromocytomas (PC) can be challenging particularly if the tumour is small. Detection of metastatic disease is important for comprehensive management of malignant PC/PGL. Somatostatin receptor imaging (SRI) agents have high sensitivity for these tumours, particularly the DOTA family of radiopharmaceuticals labelled with Gallium.
View Article and Find Full Text PDF